Isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2), encoded by the IDH1 and IDH2 genes, respectively, catalyze oxidative decarboxylation of isocitrate into α-ketoglutarate (α-KG). Gain-of-function mutations in the IDH genes are associated with aberrant conversion of α-KG to 2-hydroxyglutarate (2-HG), which is an oncogenic metabolite, and are recurrent in myeloid malignancies and glioma.1-3
Mutations in IDH1 exon 4 (7%-14%) and IDH2 exon 4 (8%-19%) are relatively common in patients with acute myeloid leukemia (AML) and have been associated with an unfavorable prognosis and inferior overall survival in some studies.1,2 IDH inhibitors have been approved by the US Food and Drug Administration (FDA) for treatment of adult patients with relapsed or refractory AML who have an IDH mutation.4,5